Stay updated on Covalent Menin Inhibitor BMF-219 Clinical Trial
Sign up to get notified when there's something new on the Covalent Menin Inhibitor BMF-219 Clinical Trial page.

Latest updates to the Covalent Menin Inhibitor BMF-219 Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.3%
- Check16 days agoNo Change Detected
- Check23 days agoChange DetectedThe web page has been updated to reflect a new version, changing from v2.14.4 to v2.15.0.SummaryDifference0.9%
- Check30 days agoChange DetectedThe web page has updated its version from v2.14.3 to v2.14.4, and a date has been added for February 7, 2025. However, there are no significant changes in core content, pricing, or availability.SummaryDifference0.9%
- Check74 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference5%
- Check88 days agoChange DetectedThe page indicates that Biomea Fusion, Inc. has terminated its pursuit of oncology indications for BMF-219, and some NLM-NCBI services are experiencing heavy traffic, which may affect performance. Additionally, a date of 2025-02-07 has been added.SummaryDifference10%
- Check95 days agoChange DetectedThe website has been updated from version v2.14.1 to v2.14.2.SummaryDifference0.3%
Stay in the know with updates to Covalent Menin Inhibitor BMF-219 Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Covalent Menin Inhibitor BMF-219 Clinical Trial page.